Intellia Therapeutics (NTLA) AI Stock Analysis

• Market Cap: $1.62B
• Dividend Yield: N/A
• Average Volume (3M): 4.60M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.22
• Revenue Growth: 33.52%
• EPS Growth: 21.66%
• Country: US
• Employees: 403
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.92
• Shares Outstanding: 115,829,926
• 10 Day Avg. Volume: 6,877,314
• 30 Day Avg. Volume: 4,597,957
• PEG Ratio: 0.71
• Price to Book (P/B): 1.32
• Price to Sales (P/S): 19.91
• P/FCF Ratio: -3.25
• Enterprise Value/Market Cap: 0.93
• Enterprise Value/Revenue: 26.17
• Enterprise Value/Gross Profit: -70.27
• Enterprise Value/Ebitda: -3.30
• 1Y Price Target: $15.13
• Price Target Upside: 2.02% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 19
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 52 Neutral
• Price Target: $14.00 ▼(-5.60% Downside)

Overall score reflects very weak profitability and persistent cash burn as the primary constraint, partially offset by a relatively solid balance sheet/cash runway and positive price momentum. The outlook is further capped by the nex-z FDA clinical hold and associated safety concerns, while valuation metrics provide limited support due to negative earnings and no dividend yield.

Positive Factors

Modest leverage / stronger balance sheet

Low reported leverage gives Intellia structural financial flexibility to fund clinical programs and negotiate partnerships without heavy near-term reliance on debt. For a development-stage biotech, modest debt reduces insolvency risk and supports strategic options across development timelines.

Cash runway into mid-2027

A clear cash runway that spans key development milestones (Phase III readouts and planned BLA timing) materially lowers near-term financing urgency. This enables focused execution on lonvo-z clinical/commercial plans, giving management time to secure non-dilutive partnerships or staged financing tied to de-risking events.

Lonvo‑z Phase III progress and BLA timeline

Completion of Phase III enrollment and a defined regulatory path represent durable clinical progress toward commercialization. If results meet endpoints, lonvo‑z could create a one-time curative revenue stream, shifting Intellia from discovery-stage funding dependence to product-driven cash generation over the medium term.

Negative Factors

FDA clinical hold on nex‑z Phase 3 trials

A regulatory clinical hold on the flagship nex‑z program due to a fatal adverse event imposes material timeline and de-risking uncertainty. Beyond delays, it raises persistent regulatory and safety questions for in vivo CRISPR platforms, potentially complicating future approvals and increasing required confirmatory work.

Sustained and sizable cash burn

Consistent, large negative operating and free cash flows signal ongoing financing needs to sustain R&D and trials. Over multiple quarters this creates durable dilution risk or dependence on milestone-driven partnerships; it also constrains the company's ability to expand programs absent material revenue or non-dilutive funding.

Deep unprofitability and shrinking equity/assets

Very large negative margins and declining equity reflect that operations are not self-funding and that prior losses have eroded balance-sheet buffers. Structurally, this heightens execution risk: success must come from pivotal trial outcomes or partnerships to restore profitability and capitalize long-term platform value.

Intellia Therapeutics Business Overview & Revenue Model

Company Description

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

How the Company Makes Money

Intellia Therapeutics generates revenue through a combination of research collaborations, licensing agreements, and potential future product sales. The company often partners with larger pharmaceutical firms, which provide upfront payments and milestone payments tied to the achievement of specific development goals. Additionally, Intellia may receive royalties on the sales of any products developed through these collaborations. As the company advances its clinical programs and moves closer to commercialization, it may also begin to realize revenue from product sales once its therapies receive regulatory approvals. Key partnerships with organizations such as Regeneron Pharmaceuticals enhance its research capabilities and financial resources, contributing significantly to its earnings potential.

Intellia Therapeutics Financial Statement Overview

Summary

Financial profile is dominated by deep losses and heavy cash burn (TTM net margin ~-775%, operating cash flow about -$411M and free cash flow about -$413M), partially offset by a relatively stronger balance sheet with modest leverage (debt-to-equity ~0.13) and significant cash resources noted in recent disclosures.

Income Statement

NTLA remains a deeply unprofitable development-stage biotech. Revenue is small and uneven, with TTM (Trailing-Twelve-Months) revenue up 8.8% versus the prior year, but profitability deteriorated materially: TTM gross profit turned negative and operating losses remain very large relative to revenue (TTM net margin roughly -775%). While annual gross margins were strong in 2021–2024, the TTM reversal highlights volatility in the revenue mix and limited operating leverage.

Balance Sheet

The balance sheet is a relative strength: leverage is modest with low debt versus equity (debt-to-equity ~0.13 in TTM, improving from ~0.24 in 2024). However, equity and total assets have trended down from 2021–2023 levels, consistent with ongoing losses and cash burn. Returns remain sharply negative (TTM return on equity about -57%), signaling the business is still far from self-funding.

Cash Flow

Cash generation is weak with sustained and sizable outflows: TTM operating cash flow is about -$411M and free cash flow about -$413M. Free cash flow is slightly worse year over year (TTM free cash flow growth ~-218%), indicating accelerating burn. A positive note is that free cash flow broadly tracks reported losses (free cash flow roughly in line with net loss), suggesting losses are not being masked by large non-cash adjustments—but the absolute burn remains a key risk.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	57.53M	57.88M	36.27M	52.12M	33.05M	57.99M
Gross Profit	-21.42M	47.59M	27.30M	44.55M	26.16M	-92.41M
EBITDA	-456.10M	-523.98M	-506.31M	-450.59M	-260.96M	-130.27M
Net Income	-445.81M	-519.02M	-481.19M	-474.19M	-267.89M	-134.23M
Balance Sheet
Total Assets	925.27M	1.19B	1.30B	1.52B	1.29B	676.32M
Cash, Cash Equivalents and Short-Term Investments	511.04M	601.51M	912.22M	1.19B	748.69M	597.37M
Total Debt	97.97M	210.20M	115.35M	130.70M	74.02M	39.30M
Total Liabilities	176.85M	319.06M	250.81M	284.53M	254.22M	149.25M
Stockholders Equity	748.42M	871.96M	1.05B	1.24B	1.04B	527.07M
Cash Flow
Free Cash Flow	-412.63M	-354.66M	-408.07M	-391.68M	-237.79M	-53.50M
Operating Cash Flow	-410.65M	-348.88M	-394.09M	-333.29M	-225.03M	-49.91M
Investing Cash Flow	352.06M	125.57M	-31.35M	160.31M	-550.78M	-214.49M
Financing Cash Flow	131.83M	185.75M	130.32M	582.96M	736.69M	371.78M

Intellia Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 14.83
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NTLA, the sentiment is Positive. The current price of 14.83 is above the 20-day moving average (MA) of 11.61, above the 50-day MA of 10.01, and above the 200-day MA of 11.68, indicating a bullish trend. The MACD of 1.28 indicates Negative momentum. The RSI at 68.85 is Neutral, neither overbought nor oversold. The STOCH value of 65.30 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NTLA.

Intellia Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
KURA	63 Neutral	$745.74M	-3.42	-65.10%	―	―	-5.18%
CMPX	58 Neutral	$1.10B	-14.01	-37.82%	―	-100.00%	-28.79%
BCAX	56 Neutral	$899.52M	-7.52	-26.64%	―	―	-103.95%
NTLA	52 Neutral	$1.62B	-3.48	-52.11%	―	33.52%	21.66%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ABCL	49 Neutral	$1.24B	-6.92	-16.81%	―	7.16%	3.95%
JANX	49 Neutral	$880.56M	-8.79	-12.48%	―	-23.37%	-42.45%

Intellia Therapeutics Corporate Events

FDA Lifts Hold on Intellia’s MAGNITUDE-2 Trial

On January 27, 2026, Intellia Therapeutics announced that the U.S. Food and Drug Administration lifted the clinical hold on its investigational new drug application for the MAGNITUDE-2 Phase 3 trial of nexiguran ziclumeran in patients with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN), a hold that had been imposed on October 29, 2025 after a MAGNITUDE trial patient experienced severe liver toxicity and subsequently died. Following alignment with the FDA on protocol modifications and enhanced liver safety monitoring, Intellia plans to resume enrollment and dosing in MAGNITUDE-2, expand target enrollment from about 50 to 60 patients, and continue evaluating the efficacy and safety of a single 55 mg infusion of nex-z versus placebo; however, the separate MAGNITUDE Phase 3 trial in ATTR-CM remains on clinical hold as discussions with the agency continue, leaving a key part of the nex-z program and Intellia’s broader ATTR strategy still subject to regulatory uncertainty for patients, investigators and investors.

The most recent analyst rating on (NTLA) stock is a Hold with a $14.50 price target. To see the full list of analyst forecasts on Intellia Therapeutics stock, see the NTLA Stock Forecast page.

Intellia Updates Investors on Nex-Z Trial Safety Hold

On January 9, 2026, Intellia Therapeutics updated its corporate presentation to investors, detailing the status of its CRISPR-based pipeline and providing additional disclosure on a serious safety event tied to its lead ATTR amyloidosis candidate, nexiguran ziclumeran (nex-z). The company reiterated that a patient in the Phase 3 MAGNITUDE trial for transthyretin amyloidosis with cardiomyopathy experienced Grade 4 liver transaminase elevations and increased bilirubin, triggering a protocol-mandated trial pause and prompting the U.S. Food and Drug Administration to impose a clinical hold on both the MAGNITUDE and MAGNITUDE-2 Phase 3 studies; the patient subsequently died on November 5, 2025, with the principal investigator attributing the death to septic shock from a perforated duodenal ulcer amid a complex clinical course that included acute liver injury treated with corticosteroids. Intellia reported that more than 650 patients with ATTR-CM and 47 patients with hereditary ATTR amyloidosis with polyneuropathy have been enrolled across the two trials, with Grade 4 liver enzyme elevations observed in less than 1% of MAGNITUDE participants and none in MAGNITUDE-2, and said it will update stakeholders once it has agreed with regulators on a path forward for nex-z, underscoring both the regulatory risk around its flagship ATTR program and the broader safety and development uncertainties facing first-in-class in vivo CRISPR therapies.

The most recent analyst rating on (NTLA) stock is a Hold with a $12.00 price target. To see the full list of analyst forecasts on Intellia Therapeutics stock, see the NTLA Stock Forecast page.

Intellia Reports Favorable Phase 1 Data for Nex-Z

On November 8, 2025, Intellia Therapeutics announced positive results from its Phase 1/2 trial of lonvoguran ziclumeran (lonvo-z) for hereditary angioedema, showing significant reductions in plasma kallikrein and a favorable safety profile. The trial results, presented at a scientific meeting, suggest lonvo-z could become a one-time treatment option, with a Phase 3 trial ongoing. On November 10, 2025, Intellia also reported favorable Phase 1 data for nexiguran ziclumeran (nex-z) in transthyretin amyloidosis with cardiomyopathy, demonstrating sustained serum TTR reduction and disease stabilization. However, the FDA placed a clinical hold on the Phase 3 trials for nex-z, impacting its development timeline.

The most recent analyst rating on (NTLA) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Intellia Therapeutics stock, see the NTLA Stock Forecast page.

Intellia Therapeutics Faces FDA Clinical Hold on Trials

On October 29, 2025, Intellia Therapeutics was informed by the FDA of a clinical hold on their Phase 3 trials for nexiguran ziclumeran due to safety concerns. The hold follows reports of severe liver issues in a patient, prompting the company to pause the trials and work with the FDA to resolve the matter.

The most recent analyst rating on (NTLA) stock is a Hold with a $14.50 price target. To see the full list of analyst forecasts on Intellia Therapeutics stock, see the NTLA Stock Forecast page.